Current diagnosis of AML requires the presence of ≥20% myeloid blasts circulating or in the bone marrow; in addition, diagnosis of AML is implied in the presence of certain recurrent cytogenetic abnormalities, such as t(8;21)(q22;q22.1)(RUNX1-RUNX1T1), inv(16)(p13.1q22) or t(16;16)(p13.1;q22)(CBFB-MYH11), and t(15;17)(q22;q12)(PML/RARA), regardless of the blast percentage1,2. The gene discussed is RARA; the disease is acute myeloid leukemia.